Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma

Katharina Schwamborn, Marcus Gorschlüter, Axel Glasmacher, Ingo G. H. Schmidt-Wolf & German Refractory Myeloma Study Group
Purpose: Introduction of lenalidomide has expanded the therapeutic options for refractory and recurrent multiple myeloma (MM) patients. However, the application of the approved doses may be difficult in some patients due to adverse effects. Experimental design: Therefore, we evaluated the efficacy and safety of lenalidomide in 10 patients with relapsed and refractory MM who received a reduced dose due to leukopenia (4), polyneuropathy (1), muscle cramps (1), thrombocytopenia (1), renal insufficiency (1), at the request...